SCHEMBL6837252

SCHEMBL6837252

FC(F)(F)C(F)(F)[Zn]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2992041 0.72
Iodide SCHEMBL9721836 0.71 LMNA (0.32)
SCHEMBL5359711 0.71
Iodide SCHEMBL11020380 0.67
Hydrochloric Acid SCHEMBL1452996 0.67
Bromide SCHEMBL9810690 0.67
Hydrochloric Acid SCHEMBL10418030 0.64
SCHEMBL44994 0.63
SCHEMBL10416601 0.62
Perfluorocyclobutane SCHEMBL8841181 0.59 MEN1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015018855-A1 PENTAFLUOROETHYLATING COMPOSITIONS FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ES) 2015-02-12 WO disclosed
EP-2835374-A1 Pentafluoroethylating compositions Fundació Institut Català d'Investigació Química (ES) 2015-02-11 EP disclosed
US-20040049072-A1 RXR modulators with improved pharmacologic profile LIGAND PHARMACEUTICALS INC 2004-03-11 US disclosed
US-6593493-B1 2-(Carboxy(unsaturated)alkyl)-1-(haloalkoxy)benzene derivatives; retinoid X receptors; cardiovascular, skin, eating and vision disorders; anticarcinogenic agents; non-insulin-dependent diabetes LIGAND PHARMACEUTICALS, INC. 2003-07-15 US disclosed
EP-1216221-A2 RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE LIGAND PHARMACEUTICALS INCORPORATED (US) 2002-06-26 EP disclosed
WO-2001019770-A2 RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE LIGAND PHARMACEUTICALS INCORPORATED (US) 2001-03-22 WO disclosed